Persistence of Weekly Injectable Semaglutide Use in Patients with Diabetes Mellitus and Obesity: A Retrospective Follow-Up in Colombia
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Semaglutide is an effective antidiabetic agent that is injected weekly to induce weight reduction, and the impact on cardiovascular outcomes is favorable. OBJECTIVE: The aim was to evaluate the persistence of the use of weekly injectable semaglutide in Colombia for 12 months among new users. METHODS: A retrospective longitudinal follow-up study of a cohort of patients with a new prescription of weekly injectable semaglutide between January and December 2022 and persistence for 365 days was evaluated. Kaplan‒Meier survival analyses were performed to evaluate the survival effect of semaglutide. RESULTS: In total, 9356 new users of semaglutide were identified. The average age of the users was 61.6 ± 12.9 years, the main diagnoses were type 2 diabetes mellitus (43.8%) and obesity (41.8%), and 90.8% of them received the 0.25/0.5-mg dose. The mean duration of use was 93.7 ± 76.3 days, but only 13.8% and 0.2% of patients continued the treatment at 6 and 12 months of follow-up, respectively. In total, 35.4% had a prescription for a single month. The other concomitant antidiabetic drugs used were metformin (43.5%), sodium glucose-2 cotransporter inhibitors (38.3%) and insulin (18.2%). CONCLUSIONS: Most of the patients started semaglutide at the suggested doses to continue with staging; however, the persistence of use was low, which may be related to difficulties in access, education on application methods, drug tolerability, and lack of follow-up by the clinician.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“| Colombia (nationwide registers) [49] | Mixed | 35.4% discontinuation after one month of therapy | 13.8% at 6 months; 0.2% at 12 months | Limited access; prohibitive out-of-pocket costs; insufficient clinical follow-up |”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“persistence fell from 35.4% at one month to 13.8% at six months and 0.2% at twelve months—a trajectory consistent with progressive financial exhaustion rather than therapeutic failure per se [49].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [49]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A 2025 retrospective study of 9356 new semaglutide users in Colombia documented a rapid decline in the persistence curve. Despite over 90% of patients initiating therapy at the recommended starting doses, 35.4% abandoned treatment after a single month, with a mean duration of use of only 93.7 days. By six months, persistence had fallen to 13.8%, and at 12 months, only 0.2% of the cohort remained”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [49]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the Colombian semaglutide cohort, where mean out-of-pocket expenditure exceeded USD 300 per month and most patients lacked supplementary private insurance coverage”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“In addition to adequate comprehensive management of cardiovascular risk, these drugs mitigate potential disease complications, improve quality of life, and decrease mortality [4–7].”
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 2×
“…in the SUSTAIN-6 study, semaglutide significantly reduced the incidence of the main outcome, namely, MACE, and this was accompanied by a lower frequency of adverse effects than that in the placebo group but a higher probability of discontinuation of therapy due to gastrointestinal problems [6].”
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 2×
“…without T2DM was shown to be highly effective in achieving weight reduction compared with the placebo (−12.7 kg) after a follow-up of 68 weeks [9], although the probability of discontinuation of therapy was higher than that with the placebo due to gastrointestinal events (in up to 50% of…”
InfluentialChatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577 · cited 2×
“In addition to adequate comprehensive management of cardiovascular risk, these drugs mitigate potential disease complications, improve quality of life, and decrease mortality [4–7].”
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“In addition, they inhibit glucagon secretion and have other systemic effects, such as changes in intestinal transit and gastric emptying, as well as effects on the central nervous system, altering the sensation of satiety and appetite [8].”
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s009 · Cited by 851 · cited 2×
“Notably, fewer than half of the patients received metformin, both in those with a primary diagnosis of T2DM and those with obesity, which may be consistent with current recommendations for first-line antidiabetic therapy in certain groups of patients [17].”
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814 · cited 1×
“The limited persistence of use can also be associated with access difficulties, delays in the approval of treatment by insurers, or ignorance, fear, or lack of training regarding the correct subcutaneous application of the drug [26, 27].”
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 1×
“The limited persistence of use can also be associated with access difficulties, delays in the approval of treatment by insurers, or ignorance, fear, or lack of training regarding the correct subcutaneous application of the drug [26, 27].”
Type-2 diabetes mellitus and cardiovascular disease
Henning, R. J. (2018) · Future Cardiology · doi:10.2217/fca-2018-0045 · Cited by 398 · cited 1×
“The management of T2DM involves nonpharmacological strategies related to changes in lifestyle, which promote a healthy diet, aerobic exercise, and the avoidance of tobacco consumption [4, 5].”
Diabetes: Advances in Diagnosis and Treatment
Nathan, D. M. (2015) · JAMA · doi:10.1001/jama.2015.9536 · Cited by 384 · cited 1×
“Among the injectables are other GLP1-RAs (liraglutide, semaglutide, or dulaglutide) and short-and long-acting human or similar insulins [2–6].”
Simms-Williams, N., Treves, N., Yin, H., Lu, S., Yu, O., Pradhan, R., Renoux, C., Suissa, S., & Azoulay, L. (2024) · BMJ · doi:10.1136/bmj-2023-078242 · Cited by 151 · cited 1×
“Interestingly, the frequency of coprescription of iSGLT2, in more than a third of the cases, may be an indicator of high cardiovascular risk or kidney damage in this group of patients and represents the need for drugs with cardiovascular protection benefits [19, 20].”
Guerci, B., Chanan, N., Kaur, S., Jasso-Mosqueda, J. G., & Lew, E. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0590-x · Cited by 106 · cited 2×
“Persistence and adherence can be affected by different factors, ranging from the form and ease of use of the drugs to access on a continuous basis and can even be affected by the expectations of the patient and the effectiveness and tolerability of the drug [11, 12].”
Kim, N., Wang, J., Burudpakdee, C., Song, Y., Ramasamy, A., Xie, Y., Sun, R., Kumar, N., Wu, E. Q., & Sullivan, S. D. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.7.740 · Cited by 81 · cited 1×
“This information should be of special interest to those responsible for the insurance and care of this group of patients and the implementation of multidisciplinary management strategies that require adherence to and persistence of antidiabetic treatment [21].”
Difficulty adhering to antidiabetic treatment: Factors associated with persistence and compliance
Guénette, L., Moisan, J., Breton, M. ‐., Sirois, C., & Grégoire, J. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.12.005 · Cited by 73 · cited 1×
“Persistence and adherence can be affected by different factors, ranging from the form and ease of use of the drugs to access on a continuous basis and can even be affected by the expectations of the patient and the effectiveness and tolerability of the drug [11, 12].”
Uzoigwe, C., Liang, Y., Whitmire, S., & Paprocki, Y. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01053-7 · Cited by 62 · cited 2×
“In a study by Uzoigwe et al. published in 2021 in the United States, with data from real-world studies, persistence of use by 67% of the participants was observed after 1 year of follow-up [10].”
InfluentialAn Epidemiologic Analysis of Diabetes in Colombia
Vargas‐Uricoechea, H., & Casas, L. Á. (2015) · Annals of Global Health · doi:10.1016/j.aogh.2015.11.001 · Cited by 54 · cited 1×
“As a contributor to this figure, Colombia ranks second in the region after Brazil, and it is estimated that T2DM affects more than 2 million Colombians, although only between 24 and 50% of cases are diagnosed [1–3].”
Singh, A. K., & Singh, R. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i6.329 · Cited by 35
Franco, J., & Vizcaya, D. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.661 · Cited by 29 · cited 1×
“On the basis of the information on the drug consumption of the affiliated population systematically obtained by the dispensing company (Audifarma SA) [13], the information was extracted via a query in Oracle SAP.”
Effectiveness and clinical inertia in patients with antidiabetic therapy
Machado‐Duque, M. E., Ramírez-Riveros, A. C., & Machado‐Alba, J. E. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12954 · Cited by 26 · cited 1×
“The average age of the analyzed population was 61.6 years, with a female predominance, which is consistent with published studies of antidiabetic therapy in Colombia [15].”
InfluentialSelf-citationLajthia, E., Bucheit, J. D., Nadpara, P. A., Dixon, D. L., Caldas, L. M., Murchie, M., & Sisson, E. M. (2019) · Pharmacy Practice · doi:10.18549/pharmpract.2019.4.1588 · Cited by 25 · cited 2×
“This group of patients received concomitant metformin (43.5%), iSGLT2 (38.3%), and basal insulin (18.2%), but 14.1% had a prescription for some iDPP4 drugs (combination not recommended [14]).”
InfluentialMody, R., Manjelievskaia, J., Marchlewicz, E. H., Malik, R. E., Zimmerman, N. M., Irwin, D. E., & Yu, M. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.01.017 · Cited by 22 · cited 1×
“…contrasts with that reported by Mody et al. in the United States from retrospective information on claims from three IBM Mar-ketscan databases; the report indicated that the average persistence was 220 days, and 42.3% of the patients continued to receive the drug after 1 year of follow-up [22].”
InfluentialValladales‐Restrepo, L. F., Sánchez-Ramírez, N., Usma-Valencia, A. F., Gaviria‐Mendoza, A., Machado‐Duque, M. E., & Machado‐Alba, J. E. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2178900 · Cited by 21 · cited 1×
“However, it differs in terms of the management of obesity with orlistat or liraglutide, since a higher proportion of women and a lower average age (47 years) have been reported [16].”
Self-citationPérez, C. T. (2025) · Diabetes Care · doi:10.2337/dc25-0566 · Cited by 3 · cited 1×
“It is possible that patients who started on the 1-mg dose began with “clicks” (microdosing) [25].”
Cárdenas‐Salas, J., Sierra-Poyatos, R., Luca, B. L., Sánchez-Lechuga, B., Móstoles, N. M., Álvarez, T. M., Montes, M. D. L. P. G., Ruiz-Sánchez, J. G., Meneses, D., Sánchez-Lopez, R., et al. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108874 · Cited by 2 · cited 1×
“%) of treatment discontinuation, mainly due to gastrointestinal adverse events (5.2%), leading to sustained improvements in glycemic control and weight [23].”
Influential
Cited by
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
Brisson, J., Castro-Arteaga, M., Logie, C. H., & Perez‐Brumer, A. (2026) · Social Science & Medicine · doi:10.1016/j.socscimed.2026.119357 · Cited by 2
Metadata
- Authors
- Machado-Duque, M. E., Gaviria-Mendoza, A., Valladales-Restrepo, L. F., & Machado-Alba, J. E.
- ORCID
- Venue
- Drugs - Real World Outcomes
- Published
- 2025-10-03
- Volume
- 12
- Issue
- 4
- Pages
- 615-622
- ISSN
- 2198-9788 (ISSN-L)
- 2199-1154
- PMC
- PMC12635016
- OpenAlex
- W4414773967
- Cited by
- 2
- References
- 25
- Citations by year
- 2026: 2
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Drugs - Real World Outcomes (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, treatment persistence, type 2 diabetes, obesity, GLP-1 receptor agonists, weight loss, antidiabetic drugs, metformin, SGLT2 inhibitors, insulin, drug tolerability, access to medicines, Colombia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

